These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 29658378

  • 1. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and 18fluorodeoxyglucose (FDG) positron emission tomography (PET).
    Kim SJ, Park MY, Pak K, Han J, Kim GW, Kim HS, Ko HC, Kim MB, Kim BS.
    J Dermatolog Treat; 2018 Dec; 29(8):761-768. PubMed ID: 29658378
    [Abstract] [Full Text] [Related]

  • 2. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose PET/CT.
    Kim BS, Lee WK, Pak K, Han J, Kim GW, Kim HS, Ko HC, Kim MB, Kim SJ.
    J Am Acad Dermatol; 2019 May; 80(5):1322-1331. PubMed ID: 29559399
    [Abstract] [Full Text] [Related]

  • 3. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.
    Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1063-70. PubMed ID: 25490866
    [Abstract] [Full Text] [Related]

  • 4. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T.
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [Abstract] [Full Text] [Related]

  • 5. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
    Stull DE, Griffiths CEM, Gilloteau I, Zhao Y, Guana A, Finlay AY, Sherif B, Houghton K, Puig L.
    Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
    [Abstract] [Full Text] [Related]

  • 6. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
    Hesselvig JH, Egeberg A, Loft ND, Zachariae C, Kofoed K, Skov L.
    Acta Derm Venereol; 2018 Mar 13; 98(3):335-339. PubMed ID: 29110019
    [Abstract] [Full Text] [Related]

  • 7. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI, PEARL investigators.
    J Drugs Dermatol; 2012 Aug 13; 11(8):943-9. PubMed ID: 22859239
    [Abstract] [Full Text] [Related]

  • 8. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB.
    J Am Acad Dermatol; 2010 Sep 13; 63(3):457-65. PubMed ID: 20462664
    [Abstract] [Full Text] [Related]

  • 9. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis.
    Hwang YJ, Youn SW, Kim BR, Yu DY, Kim Y, Pires A, Cho S, Seo SJ, Lee ES, Roh JY, Choi GS, Lee MG, MARCOPOLO investigators.
    J Dermatol; 2017 May 13; 44(5):560-566. PubMed ID: 27864841
    [Abstract] [Full Text] [Related]

  • 10. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Milutinovic M, Thaçi D.
    J Am Acad Dermatol; 2017 Jan 13; 76(1):60-69.e9. PubMed ID: 27663079
    [Abstract] [Full Text] [Related]

  • 11. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.
    Puig L, Augustin M, Blauvelt A, Gottlieb AB, Vender R, Korman NJ, Thaçi D, Zhao Y, Gilloteau I, Sherif B, Williams N, Guana A, Lebwohl MG.
    J Am Acad Dermatol; 2018 Apr 13; 78(4):741-748. PubMed ID: 29066271
    [Abstract] [Full Text] [Related]

  • 12. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N, Noda S, Taniguchi T, Adachi M.
    Int J Dermatol; 2015 Oct 13; 54(10):1194-8. PubMed ID: 26016819
    [Abstract] [Full Text] [Related]

  • 13. Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study.
    Savage L, Goodfield M, Horton L, Watad A, Hensor E, Emery P, Wakefield R, Wittmann M, McGonagle D.
    Arthritis Rheumatol; 2019 Apr 13; 71(4):626-631. PubMed ID: 30468001
    [Abstract] [Full Text] [Related]

  • 14. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG.
    Br J Dermatol; 2010 Jan 13; 162(1):137-46. PubMed ID: 19903183
    [Abstract] [Full Text] [Related]

  • 15. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
    Prieto-Pérez R, Llamas-Velasco M, Cabaleiro T, Solano-López G, Márquez B, Román M, Ochoa D, Talegón M, Daudén E, Abad-Santos F.
    Pharmacogenomics; 2017 Jan 13; 18(2):157-164. PubMed ID: 27977334
    [Abstract] [Full Text] [Related]

  • 16. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
    Chiu HY, Chu TW, Cheng YP, Tsai TF.
    PLoS One; 2015 Jan 13; 10(11):e0142930. PubMed ID: 26566272
    [Abstract] [Full Text] [Related]

  • 17. Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital.
    Elberdín L, Fernández-Torres R, Paradela S, Blanco E, Outeda M, Martín I, Fonseca E.
    J Dermatolog Treat; 2020 Nov 13; 31(7):698-701. PubMed ID: 30961404
    [Abstract] [Full Text] [Related]

  • 18. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
    Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, Rastogi S, Pillai R, Israel R.
    J Eur Acad Dermatol Venereol; 2018 Aug 13; 32(8):1305-1313. PubMed ID: 29512200
    [Abstract] [Full Text] [Related]

  • 19. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
    Blauvelt A, Reich K, Mehlis S, Vanaclocha F, Sofen H, Abramovits W, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tyring S.
    J Eur Acad Dermatol Venereol; 2017 Oct 13; 31(10):1693-1699. PubMed ID: 28602039
    [Abstract] [Full Text] [Related]

  • 20. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis.
    Au SC, Goldminz AM, Kim N, Dumont N, Michelon M, Volf E, Hession M, Lizzul PF, Andrews ID, Kerensky T, Wang A, Yaniv S, Gottlieb AB.
    J Dermatolog Treat; 2013 Jun 13; 24(3):179-87. PubMed ID: 22390688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.